Science is largely close and reproducible examination of relationships between physical phenomena. It was by looking at the relationship between electricity and magnetism and the relativity of their effects that scientists created a whole revolution in scientific thinking, leading from Michael Faraday to Albert Einstein. The relationship between phenomena and time has a very long history. The word 'kinetic' refers to movement, displacement, usually in relation to time or space.
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Dost was a German pediatrician who used mathematical calculations to optimize drug doses in children. The purpose of pharmacokinetics is to study the time course of drug and metabolite concentrations or amounts in biological fluids, tissues and excreta, and of pharmacological response, and to construct suitable models to interpret such data. In pharmacokinetics, data are analyzed using a mathematical representation of a part or the whole of an organism. His studies opened a new way of thinking of drug concentrations and optimization of therapies in every aspect of clinical pharmacology. In remembrance of him, the German Society for Clinical Pharmacology hosts an annual award, the Friedrich-Hartmut-Dost Memorial Prize, to promote clinical pharmacology in the European countries.
in an individual or a population. It is the basis of therapeutic drug monitoring with the ultimate goal of keeping drugs safe. Initial studies of the subject were published in journals of physiology and biochemistry. From Germany, in 1913, Michaelis By measuring plasma metoprolol concentration, Iyun and colleagues in 1986 described the role of genetic polymorphism in the oxidative metabolism of metoprolol and debrisoquin. He concluded that in ethnic studies of drug metabolism each racial group should be examined separately for evidence of polymorphic metabolism and antimodes should not be extrapolated from one population to another. 4 Prof. AO Iyun In 1988, Iyun and colleagues evaluated the phar macokinetics of digoxin in eight healthy volunteers, 23 congestive cardiac failure, and 10 chronic renal failure patients. They found that the mean serum digoxin concentrations in the volunteers and the congestive cardiac failure patients were significantly different from those in the chronic renal failure patients. They also found that the mean half-life of digoxin in the healthy volunteers (37.2 h +/-8.6 s.d.) was comparable to the widely accepted 40 h for digoxin half-life in normal individuals. He recommended that in the absence of renal impairment and hypokalaemia, standard dosages of digoxin could be used in congestive cardiac failure patients, provided symptoms and signs of toxicity are constantly monitored. Iyun also recommended that therapeutic drug monitoring of digoxin is desirable in view of its low toxicity: therapeutic ratio, and its kinetics should be studied in detail in each community to establish correct dosages to prevent and manage digoxin toxicity. 5 Nadolol is a non-selective beta-blocker used in the treatment of hypertension and long-term management of angina pectoris. The drug is 30% bound to protein and has a half-life of 14 -24 hours. Side effects include dizziness and fatigue. In 1989, Prof Iyun and colleagues reported clinical experience with nadolol in Nigerian patients with essential hypertension. 6 Although the study did not report measurement of Nadolol concentrations over time, Iyun closely observed changes in cardiovascular parameters over time. He discovered that Nadolol was highly effective in 15 patients (65.2%) moderately effective in 6 patients (26%) and ineffective in 2 patients (8.6%). He also stated that side effects were not a problem in this study and tolerance to the drug was excellent in most cases. 7 and pindolol in hypertensive Africans. Salako and colleagues found that Pindolol diminished systolic blood pressure at rest and after exercise and antagonized exercise-induced tachycardia, but had no effect on resting heart rate and that Propranolol diminished systolic blood pressure predominantly after exercise and reduced both resting and exercise heart rate. Both drugs had no effect on diastolic pressure. In 1971 Salako had written a paper on oral thiazide diuretics in the treatment of hypertension in Nigeria, describing his findings. 12 He would go on to build a very illustrious career in the study of anti-hypertensive medications in Nigerians. During the period spanning 1983 -1987, Prof Salako published six significant papers on the pharmacokinetics of chloroquine and amodiaquine, the most widely used antimalarials at that time. [13] [14] [15] [16] [17] [18] He found that with each route of administration of chloroquine the area under the plasma concentration-time curve was less than that for whole blood, which was in turn less than that for red blood cells. This meant that by whatever route the drug was administered, higher concentrations were reached in red blood cells and whole blood than in plasma, but the concentrations declined at the same rate in the three media thus giving similar half-lives. He also found that the plasma, or whole blood or red blood cell, halflives varied depending upon whether the drug was given orally, intramuscularly or intravenously. Plasma chloroquine concentrations were determined using High Performance Liquid Chromatography (HPLC) method. Salako found that the plasma half-life of chloroquine was significantly higher in renal insufficiency patients than in controls. This finding suggested that extra caution should be taken when prescribing chloroquine for prolonged use in patients with renal insufficiency. By this time, Prof Salako had become an internationally renowned Pharmacologist.
In 1989, a landmark paper was published by Prof Salako and colleagues describing the Pharmacokinetics of quinine in African children suffering from kwashiorkor. 19 They found that the apparent absorption half-life of quinine was significantly longer in kwashiorkor than in controls. In addition, they discovered that the maximum concentration (Cmax) of quinine was significantly lower in kwashiorkor than in controls. Quinine was eliminated more slowly in children with kwashiorkor with the elimination halflife being significantly longer and the oral clearance significantly less than in controls. It was concluded that kwashiorkor significantly affects the pharmacokinetics of quinine, and that the effect may be due to the pathological changes in the intestine and liver in this condition. In 1992, Salako and Sowunmi reported the disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to Prof. LA Salako Prof Salako and colleagues published four significant papers in 1979; one of them reported the pharmacokinetics of pindolol in 12 hypertensive African subjects after a single oral dose of the drug. [8] [9] [10] [11] He found that the estimated pharmacokinetic parameters did not differ significantly in Africans from the values that had been observed in other races. In the same group of papers published in 1979, he described the comparative beta-adrenoreceptorblocking effects and pharmacokinetics or propranolol healthy adult Africans. 20 They found that the half-lives after the i.v. infusion did not differ from those after oral administration. His studies of antimalarial therapies are now classics; they initiated an era of superlative malaria research that continues to thrive at the department of Pharmacology and Therapeutics, University of Ibadan, to this day. In 1994, Prof Salako and colleagues described an open, non-comparative clinical trial that was carried out in Nigeria and Burkina Faso to investigate the safety and efficacy of the novel antimalarial arteflene in patients with mild malaria. 21 This study showed that a single dose of 25 mg/kg arteflene was found to be an effective and welltolerated treatment for mild P. falciparum malaria. Conducting clinical trials is a major objective of the department of Clinical Pharmacology, University College Hospital, Ibadan. The Department is one of the Legacies of Professor Lateef Akinola Salako. His career spanned through superlative animal and human research on antihypertensives, clinical trials, and malariology.
Other Notable Early Reports
Aderounmu, who was a collaborator with Professor Salako, made significant contributions to clinical phar macokinetics. She did work on the pharmacokinetics of chloroquine which on their own were landmark studies. 22, 23 Aderounmu reported that different brands of chloroquine in Nigeria, at that time, had similar bioavailability, although with some variations in pharmaceutical properties. Those were days when sub-standard products were rare or even non-existent in Nigeria. Other early workers include Ette and colleagues, who did major work on drug interactions. [24] [25] [26] [27] [28] Walker, who was in the same department with Salako, evaluated the disposition of chloroquine after oral and parenteral doses This historical review is based on publications listed on PUBMED and many other workers who made significant contributions to clinical pharmacokinetics in the early years of development of the field in Nigeria may not have been listed here. The author acknowledges this limitation. There is a need to continue updating our records of great men and women in the history of scientific research in our nation.
Evolving Relevance of Clinical Pharmacokinetics
Further growth and development of clinical pharmacokinetics will depend on vast improvements in analytical methods and accompanying technologies.
Advances in engineering will significantly determine the future utility of clinical pharmacokinetics. A miniature, non-invasive, remote, and cheap method of monitoring drug concentrations is still being developed. All advances will be centered on optimizing patient care. Future advances will include developments in the individualization of therapy, in silico drug screening and development, advances in sophisticated computer programs with advances in supercomputing, defining biological constants that will account for inter-individual variations in drug concentration-time cur ves, phar macokineticpharmacogenetic inter-phases, development of highly specialized, multidisciplinary, pharmacokinetics laboratories and therapeutic drug monitoring units, and rapid response toxicology units.
